Citation Information :
Ghosh S. Polymyxin B Plus Aerosolized Colistin vs Polymyxin B Alone in Hospital-acquired Pneumonia (“AEROCOL” Study): A Feasibility Study. Indian J Crit Care Med 2024; 28 (8):792-795.
Introduction: In hospital-acquired pneumonia (HAP) due to extensively drug resistant gram-negative pathogens, can treatment with high-dose colistin aerosolization using specific aerosol delivery protocol, improve clinical outcome in addition to systemic polymyxin-B? Materials and methods: In a randomized control trial, invasively ventilated adult ICU patients with HAP in whom clinicians decided to start systemic polypeptide antibiotics, were randomized to receive either intravenous polymyxin-B plus high-dose colistin nebulization (5-MIU 8-hourly) using specific protocol or intravenous polymyxin-B alone. Results: The study was closed early after recruiting 60% of planned patients because of slow rate of recruitment (24 patients in over 30 months). Treatment success (Primary outcome) was nonsignificantly higher in intervention group (63.66 vs 30.77%; p = 0.217). There was higher rate of microbiological cure in intervention group (60 vs 9.09%: p = 0.018). Numerically better secondary outcomes including fever-free days, ventilator- or vasopressor free days at day-7, ICU and hospital mortality also did not reach statistical significance. Two episodes of transient hypoxia were seen during aerosol delivery. However, overall incidences of adverse effects were not different between groups. Conclusion: This study could not confirm superiority of high-dose colistin aerosolization plus systemic polymyxin-B strategy over polymyxin-B alone in treating HAP due to extensive drug resistance (XDR) gram-negative pathogens.
Walia K, Madhumathi J, Veeraraghavan B, Chakrabarti A, Kapil A, Ray P, et al. Establishing antimicrobial resistance surveillance & research network in India: Journey so far. Indian J Med Res 2019;149(2):164–179. DOI: 10.4103/ijmr.IJMR_226_18.
Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, et al. Nebulized and intravenous Colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010;36(7):1147–1155. DOI: 10.1007/s00134-010-1879-4.
Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, et al. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother 2018;73(2):462–468. DOI: 10.1093/jac/dkx409.
Zhang X, Cui X, Jiang M, Huang S, Yang M. Nebulized colistin as the adjunctive treatment for ventilator-associated pneumonia: A systematic review and meta-analysis. J Crit Care 2023;77:154315. DOI: 10.1016/j.jcrc.2023.154315.
Karaiskos I, Gkoufa A, Polyzou E, Schinas G, Athanassa Z, Akinosoglou K. High-dose nebulized colistin methane sulfonate and the role in hospital-acquired pneumonia caused by gram-negative bacteria with difficult-to-treat resistance: A review. Microorganisms 2023;11(6):1459. DOI: 10.3390/microorganisms11061459.
Rouby JJ, Bouhemad B, Monsel A, Brisson H, Arbelot C, Lu Q, et al. Aerosolized antibiotics for ventilator-associated pneumonia: Lessons from experimental studies. Anesthesiology 2012;117(6):1364–1380. DOI: 10.1097/ALN.0b013e3182755d7a.
Rouby JJ, Goldstein I, Lu Q. Inhaled antibiotic therapy. In: Tobin MJ (Ed). Principles and Practice of Mechanical Ventilation. Chapter 64, 2nd edition. McGraw-Hill, New York; 2006. pp. 1311–1332.
Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized Colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65(12):2645–2649. DOI: 10.1093/jac/dkq360.
Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012;117(6):1335–1347. DOI: 10.1097/ALN.0b013e31827515de.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019;39(1):10–39. DOI: 10.1002/phar.2209.
Nation RL, Velkov T, Li J. Colistin and polymyxin B: Peas in a pod, or chalk and cheese? Clin Infect Dis 2014;59(1):88–94. DOI: 10.1093/cid/ciu213.
Chang KH, Moon SH, Oh JY, Yoon YS, Gu N, Lim CY, et al. Comparison of salbutamol delivery efficiency for jet versus mesh nebulizer using mice. Pharmaceutics 2019;11(4):192. DOI: 10.3390/pharmaceutics11040192.
Galindo-Filho VC, Alcoforado L, Rattes C, Paiva DN, Brandão SCS, Fink JB, et al. A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radio labelled aerosols. Respir Med 2019;153:60–67. DOI: 10.1016/j.rmed.2019. 05.016.
Rello J, Rouby JJ, Sole-Lleonart C, Chastre J, Blot S, Luyt CE, et al. Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect 2017;23(9):640–646. DOI: 10.1016/j.cmi.2017.03.018.
